Cerevel Therapeutics Holdings, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ronald C. Renaud Jr.,
- Full Time Employees
- 355
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 222 Jacobs Street Cambridge MA United States of America 02141
- IPO Date
- Jul 30, 2020
- CIK
- 0001805387
- Website
- cerevel.com
- Similar Companies
- Business
- Cerevel Therapeutics Holdings, Inc., operating as a subsidiary of AbbVie following its acquisition in August 2024, is a biopharmaceutical entity dedicated to advancing novel treatments for neurological and psychiatric conditions. The company's pipeline leverages a targeted approach to neuroscience, combining insights into disease biology and brain neurocircuitry with advanced chemistry to design receptor-selective therapies. Among its lead clinical programs, emraclidine, a muscarinic M4 receptor positive allosteric modulator, is currently undergoing Phase 2 trials for schizophrenia, with these studies designed to support potential regulatory submissions. Emraclidine is also being explored in Phase 1 for the treatment of Alzheimer’s disease psychosis. Tavapadon, a selective dopamine D1/D5 partial agonist, is in Phase 3 development for Parkinson’s disease, having recently demonstrated positive results in its TEMPO-3 trial as an adjunctive therapy to levodopa, significantly improving motor symptoms. Further Phase 3 studies, TEMPO-1 and TEMPO-2, are evaluating tavapadon as monotherapy, alongside a long-term safety and tolerability trial, TEMPO-4. The pipeline also includes Darigabat, an alpha 2/3/5 selective GABAA receptor positive allosteric modulator, which is progressing through Phase 2 proof-of-concept trials for patients with focal epilepsy and panic disorder. Additionally, CVL-871, a selective dopamine D1/D5 partial agonist, is in an exploratory Phase 2a trial addressing dementia-related apathy, a program which has received FDA Fast Track designation. Another candidate, CVL-354, a kappa opioid receptor antagonist, is in Phase 1 for major depressive disorder and substance use disorder. Cerevel was established in 2018 and maintains its headquarters in Cambridge, Massachusetts.
CERE DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
CERE Investors Have the Opportunity to Lead the Cerevel Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
FINAL REMINDER CERE DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Cerevel Therapeutics Holdings, Inc. Investors to Participate in the Class Action Lawsuit
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
FINAL CERE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cerevel Therapeutics Holdings, Inc. Investors to Join the Class Action Lawsuit
CERE FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
CERE DEADLINE TUESDAY: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
CERE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
CERE IMPORTANT DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
CERE Deadline: CERE Investors with Losses in Excess of $100K Have Opportunity to Lead Cerevel Therapeutics Holdings, Inc. Securities Fraud Lawsuit
CERE IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
CERE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Cerevel Therapeutics Holdings, Inc. to Contact the Firm Today!
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
CERE DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
CERE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Cerevel Therapeutics Holdings, Inc. to Contact the Firm Today!
CERE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE